Reported 3 days ago
Summit Therapeutics Inc. experienced a remarkable 33.87% increase in stock price last week, closing at $23.24, driven by positive ratings from Cantor Fitzgerald and Truist Securities. This surge comes amid a generally recovering stock market impacted by the US-China trade tensions, and SMMT's strong performance highlights its role as a prominent biopharmaceutical oncology company focusing on developing new therapies.
Source: YAHOO